Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) is a pioneering global life sciences company based in Minnesota. Specializing in bioactive tools and reagents, Bio-Techne serves the research and clinical diagnostic communities. The company's extensive product portfolio, exceeding 275,000 items, supports scientific investigations into biological processes and disease mechanisms, facilitating both drug discovery and accurate clinical testing.
Bio-Techne operates through two main segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment, which accounts for 75% of revenue, provides reagents such as antibodies and analytical instruments for life sciences research. The Diagnostics and Genomics segment, representing 25% of revenue, offers diagnostic reagents and molecular diagnostics, with a strong footprint in spatial biology products.
Geographically, the United States is Bio-Techne's largest market, contributing about 55% of its revenue. The company also maintains significant operations in Europe, the Middle East, Africa (20%), the UK (5%), and Asia-Pacific (15%).
In recent news, Bio-Techne has been active on multiple fronts:
- Legal Actions: Bio-Techne initiated legal proceedings in the Unified Patent Court to address patent infringements related to its RNAscope® ISH technology by Molecular Instruments, Inc.
- Innovations: Partnering with Novomol-Dx, Bio-Techne introduced the Bio-Marker Pathfinder (BMP), a point-of-care ocular biomarker kit leveraging its Ella™ platform for rapid diagnostics in ophthalmic diseases.
- Strategic Collaborations: Bio-Techne entered a distribution agreement with Thermo Fisher Scientific to expand product access across Europe and announced continued collaboration with Regulus Therapeutics, highlighting positive results in ADPKD treatment using Bio-Techne's Simple Western™ platforms.
- Financial Performance: Bio-Techne reported a modest 3% revenue increase for Q3 FY2024 despite challenging market conditions, underscoring strong operational execution and strategic investments.
- Product Showcases: The company unveiled its MauriceFlex™ System at the 72nd ASMS Conference, demonstrating innovative solutions for protein characterization.
With over 3,100 employees worldwide, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023. The company continues to drive significant advancements in life sciences and healthcare through its robust portfolio and strategic initiatives.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) and Novomol-Dx have developed the Bio-Marker Pathfinder (BMP), a groundbreaking ocular biomarker kit for point-of-care application. The kit, running on Bio-Techne's Ella™ platform, provides accurate, reliable data in less than 90 minutes, targeting Dry Eye Disease, Diabetic Retinopathy, and patient monitoring post-ocular surgeries. With potential applications beyond ocular diseases, the BMP kit addresses a significant unmet need in India, aiming to benefit millions of patients. The partnership between Bio-Techne and Novomol-Dx showcases the potential of biomarker research in diagnostic and prognostic applications, promising a brighter future for ocular healthcare.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
-
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has filed a patent infringement lawsuit against Molecular Instruments, Inc. in Europe to protect its patented RNAscope® ISH technology. The lawsuit alleges that Molecular Instruments' HCR 3.0 technology infringes ACD's European Patents 1,910,572 and 2,500,439. Bio-Techne aims to halt the infringement, seek damages, and obtain injunctive relief in key European markets to defend its position as a global leader in spatial biology research and clinical applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
-
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) will host a conference call on May 1, 2024, to review third quarter fiscal 2024 financial results. Bio-Techne is a leading developer of high-quality purified proteins, reagent solutions, and diagnostic products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.41%
Tags
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announces that Advanced Cell Diagnostics (ACD) has reached a milestone of over 10,000 peer-reviewed publications utilizing RNAscope™ ISH technology, solidifying its leadership in spatial biology applications. The increasing global customer awareness and market adoption signify ACD's significant impact in enabling ground-breaking biologic discoveries and therapeutic advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
-
Rhea-AI Summary
Bio-Techne (TECH) will present its cancer research solutions at the AACR annual meeting in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
-
News
Rhea-AI Summary
Bio-Techne (TECH) wins prestigious awards for its R&D Systems and Advanced Cell Diagnostics brands. The company received the 'ELISA Kit Supplier of the Year' award for its R&D Systems brand and 'The Innovation Award' for Advanced Cell Diagnostics. These accolades highlight Bio-Techne's commitment to scientific excellence and innovation in the research and clinical diagnostic communities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) announces a partnership between Lunaphore and Nikon to expand access to spatial biology services in the US. The collaboration aims to provide cutting-edge technology for researchers and clinicians to enhance spatial biology research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
-
Rhea-AI Summary
Bio-Techne's QuantideX qPCR BCR-ABL IS Kit is now compliant with the latest EU diagnostic regulations, enhancing monitoring for CML patients. The kit offers robust quantification of BCR-ABL1 and ABL1 transcripts, aiding in TKI therapy response assessment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) will have its President, Will Geist, present at the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. The presentation will be available via a live webcast on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
Rhea-AI Summary
Bio-Techne Corporation (TECH) President and CEO to present at Barclays Global Healthcare Conference. Live webcast available on Bio-Techne's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
FAQ
What is the current stock price of Bio-Techne (TECH)?
The current stock price of Bio-Techne (TECH) is $67.57 as of November 15, 2024.
What is the market cap of Bio-Techne (TECH)?
The market cap of Bio-Techne (TECH) is approximately 10.7B.
What does Bio-Techne Corporation do?
Bio-Techne Corporation provides innovative bioactive tools and reagents that support scientific investigations, drug discovery, and clinical diagnostics.
What are Bio-Techne's main business segments?
Bio-Techne operates through two main segments: Protein Sciences and Diagnostics and Genomics.
Where is Bio-Techne headquartered?
Bio-Techne is headquartered in Minnesota, USA.
Which markets does Bio-Techne serve?
Bio-Techne serves the pharma, biotech, academic, and diagnostic markets globally, with significant operations in the USA, Europe, Asia-Pacific, and other regions.
What recent legal actions has Bio-Techne taken?
Bio-Techne has taken legal action against Molecular Instruments, Inc. in the Unified Patent Court to address patent infringements related to its RNAscope® ISH technology.
What is the Bio-Marker Pathfinder (BMP) kit?
Co-developed with Novomol-Dx, the BMP kit is an ocular biomarker kit running on Bio-Techne's Ella™ platform, designed for rapid diagnostics in ophthalmic diseases.
What was Bio-Techne's financial performance in Q3 FY2024?
Bio-Techne reported a 3% revenue increase for Q3 FY2024, highlighting strong operational execution despite challenging market conditions.
What is the MauriceFlex™ System?
The MauriceFlex™ System is an imaged capillary isoelectric focusing (icIEF) solution for protein characterization, recently showcased at the ASMS Conference.
How many employees does Bio-Techne have?
Bio-Techne has approximately 3,100 employees worldwide.
What was Bio-Techne's revenue in fiscal 2023?
Bio-Techne generated over $1.1 billion in net sales in fiscal 2023.
Bio-Techne Corp.
Nasdaq:TECH
TECH Rankings
TECH Stock Data
10.74B
158.89M
1.04%
99.35%
2.27%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
MINNEAPOLIS